Apyx Medical Q2 revenue beats estimates on surgical aesthetics growth
APYX•Full-year outlook reaffirmed
Apyx Medical reaffirmed its FY2026 revenue guidance of $59.0 million to $60.0 million.
The company expects 2026 surgical aesthetics revenue of $54.0 million to $55.0 million, while OEM revenue is expected to be about $5.0 million, down from $7.5 million in 2025.
Growth drivers and segment mix
Revenue growth was driven by increased sales of AYON and Renuvion generators internationally, as well as single-use handpieces domestically. A higher percentage of surgical aesthetics sales also contributed to improved gross margin.
OEM revenue declined because of lower sales volume to existing customers.
Quarterly results beat estimates
Apyx Medical said second-quarter revenue rose 22% year over year, beating analyst expectations, as growth in its surgical aesthetics business lifted results. The company also said adjusted EBITDA loss narrowed and came in better than analysts expected.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Sales | Beat | $13.88 mln | $13.18 mln (5 Analysts) |
| Q2 Loss Per Share | $0.07 | ||
| Q2 Net Loss | $3.07 mln | ||
| Q2 Adjusted EBITDA | Beat | -$705,000 | -$1.86 mln (3 Analysts) |
| Q2 Gross Margin | 63.90% | ||
| Q2 Income From Operations | -$1.81 mln | ||
| Q2 Pretax Loss | $2.95 mln |
